NASDAQ:ALXO ALX Oncology (ALXO) Stock Forecast, Price & News $4.80 -0.15 (-3.03%) (As of 09/29/2023 08:52 PM ET) Add Compare Share Share Today's Range$4.71▼$4.9950-Day Range$4.19▼$6.1652-Week Range$3.94▼$13.64Volume133,500 shsAverage Volume228,526 shsMarket Capitalization$197.52 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ALX Oncology MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside337.5% Upside$21.00 Price TargetShort InterestBearish16.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 2 Articles This WeekInsider TradingSelling Shares$47,889 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.16) to ($3.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector372nd out of 970 stocksPharmaceutical Preparations Industry155th out of 445 stocks 3.5 Analyst's Opinion Consensus RatingALX Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.00, ALX Oncology has a forecasted upside of 337.5% from its current price of $4.80.Amount of Analyst CoverageALX Oncology has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.47% of the float of ALX Oncology has been sold short.Short Interest Ratio / Days to CoverALX Oncology has a short interest ratio ("days to cover") of 19.1, which indicates bearish sentiment.Change versus previous monthShort interest in ALX Oncology has recently decreased by 4.11%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldALX Oncology does not currently pay a dividend.Dividend GrowthALX Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALXO. Previous Next 3.3 News and Social Media Coverage News SentimentALX Oncology has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ALX Oncology this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for ALXO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows3 people have added ALX Oncology to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ALX Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,889.00 in company stock.Percentage Held by Insiders50.30% of the stock of ALX Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.37% of the stock of ALX Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ALX Oncology are expected to decrease in the coming year, from ($3.16) to ($3.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ALX Oncology is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ALX Oncology is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioALX Oncology has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ALX Oncology (NASDAQ:ALXO) StockALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company's pre-clinical program focuses on the development of ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Read More ALXO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALXO Stock News HeadlinesSeptember 30, 2023 | americanbankingnews.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Recommendation of "Buy" by BrokeragesSeptember 9, 2023 | msn.comCantor Fitzgerald Reiterates Alx Oncology Holdings (ALXO) Overweight RecommendationOctober 2, 2023 | Goldco (Ad)Biden's Digital Dollar NightmareOn July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late! September 7, 2023 | markets.businessinsider.comWhere ALX Oncology Holdings Stands With AnalystsSeptember 6, 2023 | finance.yahoo.comALX Oncology Realigns Executive Leadership TeamAugust 14, 2023 | msn.comCantor Fitzgerald Maintains Alx Oncology Holdings (ALXO) Overweight RecommendationAugust 12, 2023 | msn.comPiper Sandler Maintains Alx Oncology Holdings (ALXO) Overweight RecommendationAugust 11, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on ALX Oncology Holdings (ALXO)October 2, 2023 | Goldco (Ad)Biden's Digital Dollar NightmareOn July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late! August 11, 2023 | msn.comHC Wainwright & Co. Maintains Alx Oncology Holdings (ALXO) Buy RecommendationAugust 11, 2023 | markets.businessinsider.com4 Analysts Have This to Say About ALX Oncology HoldingsAugust 10, 2023 | finance.yahoo.comALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?July 26, 2023 | finance.yahoo.comALX Oncology Holdings Inc. (ALXO) Loses -18.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerJune 26, 2023 | finance.yahoo.comALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric CancerMay 12, 2023 | nasdaq.comHC Wainwright & Co. Reiterates Alx Oncology Holdings (ALXO) Buy RecommendationMay 12, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About ALX Oncology HoldingsMay 12, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for ALX Oncology Holdings (ALXO)May 12, 2023 | msn.comRecap: ALX Oncology Holdings Q1 EarningsMay 11, 2023 | seekingalpha.comALX Oncology GAAP EPS of -$0.74May 11, 2023 | finance.yahoo.comALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsApril 25, 2023 | finance.yahoo.comALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple MyelomaMarch 21, 2023 | seekingalpha.comALXO ALX Oncology Holdings Inc.March 14, 2023 | finance.yahoo.comALX Oncology and Quantum Leap Healthcare CollaborativeTM Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast CancerMarch 13, 2023 | finance.yahoo.comALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast CancerMarch 9, 2023 | finance.yahoo.comALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming MilestonesFebruary 16, 2023 | finanznachrichten.deDelveInsight Business Research, LLP: Oncology Conference Coverage Service | DelveInsightFebruary 16, 2023 | finance.yahoo.comALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial CancerSee More Headlines Receive ALXO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address ALXO Company Calendar Last Earnings8/10/2023Today10/01/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALXO CUSIPN/A CIK1810182 Webwww.alxoncology.com Phone650-466-7125FaxN/AEmployees72Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.00 High Stock Price Forecast$34.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+337.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.39% Return on Assets-43.17% Debt Debt-to-Equity Ratio0.04 Current Ratio12.49 Quick Ratio12.49 Sales & Book Value Annual Sales$1.18 million Price / Sales167.39 Cash FlowN/A Price / Cash FlowN/A Book Value$6.46 per share Price / Book0.74Miscellaneous Outstanding Shares41,150,000Free Float20,453,000Market Cap$197.52 million OptionableNot Optionable Beta1.72 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Corey S. Goodman Ph.D. (Age 71)Exec. Chairman Comp: $84kMr. Jason W. Lettmann (Age 46)CEO & Director Comp: $60.5kDr. Jaume Pons Ph.D. (Age 57)Founder, Pres, Director & Chief Scientific Officer Comp: $856.29kMr. Peter S. Garcia M.B.A. (Age 61)Chief Financial Officer Comp: $631.11kDr. Sophia Randolph M.D. (Age 55)Ph.D., Chief Medical Officer & Director Comp: $637.24kDr. Michael Chang Ph.D.VP of OperationsMs. Shelly Pinto (Age 47)Sr. VP of Fin. & Chief Accounting Officer Dr. Christopher Byrd J.D.Ph.D., Gen. CounselMs. Jeanne Y. Jew (Age 59)Chief Bus. Officer Dr. Athanasios Tsiatis M.D.Sr. VP of Clinical Devel.More ExecutivesKey CompetitorsCorMedixNASDAQ:CRMDRigel PharmaceuticalsNASDAQ:RIGLAcrivon TherapeuticsNASDAQ:ACRVAtai Life SciencesNASDAQ:ATAISagimet BiosciencesNASDAQ:SGMTView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemSold 16,846 shares on 8/21/2023Ownership: 0.017%Alliancebernstein L.P.Bought 8,580 shares on 8/15/2023Ownership: 0.094%Wells Fargo & Company MNBought 3,928 shares on 8/15/2023Ownership: 0.022%Royal Bank of CanadaBought 2,776 shares on 8/15/2023Ownership: 0.010%Citadel Advisors LLCBought 1,100 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ALXO Stock - Frequently Asked Questions Should I buy or sell ALX Oncology stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALXO shares. View ALXO analyst ratings or view top-rated stocks. What is ALX Oncology's stock price forecast for 2023? 6 equities research analysts have issued 1 year price targets for ALX Oncology's stock. Their ALXO share price forecasts range from $8.00 to $34.00. On average, they predict the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 337.5% from the stock's current price. View analysts price targets for ALXO or view top-rated stocks among Wall Street analysts. How have ALXO shares performed in 2023? ALX Oncology's stock was trading at $11.27 at the start of the year. Since then, ALXO shares have decreased by 57.4% and is now trading at $4.80. View the best growth stocks for 2023 here. When is ALX Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our ALXO earnings forecast. How were ALX Oncology's earnings last quarter? ALX Oncology Holdings Inc. (NASDAQ:ALXO) issued its earnings results on Thursday, August, 10th. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.01. What other stocks do shareholders of ALX Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and When did ALX Oncology IPO? (ALXO) raised $128 million in an IPO on Friday, July 17th 2020. The company issued 8,000,000 shares at a price of $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor served as the underwriters for the IPO and LifeSci Capital was co-manager. What is ALX Oncology's stock symbol? ALX Oncology trades on the NASDAQ under the ticker symbol "ALXO." How do I buy shares of ALX Oncology? Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ALX Oncology's stock price today? One share of ALXO stock can currently be purchased for approximately $4.80. How much money does ALX Oncology make? ALX Oncology (NASDAQ:ALXO) has a market capitalization of $197.52 million and generates $1.18 million in revenue each year. The company earns $-123,480,000.00 in net income (profit) each year or ($3.20) on an earnings per share basis. How can I contact ALX Oncology? ALX Oncology's mailing address is 866 MALCOLM ROAD SUITE 100, BURLINGAME CA, 94010. The official website for the company is www.alxoncology.com. The company can be reached via phone at 650-466-7125 or via email at peter@alxoncology.com. This page (NASDAQ:ALXO) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.